Residency · Residency · Diagnostic Radiology

MRI Safety and Contraindications

MRI Safety Zones

ACR Four-Zone Safety Model

The American College of Radiology defines a four-zone model to manage access to the MRI environment and prevent injuries. Zone I is the general public area, including waiting rooms and hallways, with unrestricted access. Zone II is the interface between the public and MRI-controlled areas, where reception and patient screening take place. Zone III is the controlled access area where unscreened individuals could be injured; it requires physical barriers and is restricted to screened and authorized personnel. Zone IV is the scanner room itself, containing the magnet and its fringe field, and represents the highest-risk area. Only screened individuals under direct supervision should enter Zone IV. The transition from Zone III to Zone IV is the critical control point that requires oversight by Level 2 MRI Personnel.

Personnel Categories

MRI personnel are classified by their training level. Level 1 MRI Personnel have passed minimal MRI safety education and may enter Zone III. Level 2 MRI Personnel have received extensive training and serve as safety resources, ensuring the safe supervision of everyone entering Zone IV; this category includes MRI technologists and MRI safety officers. Non-MRI Personnel are individuals who do not meet Level 1 or Level 2 criteria and must be accompanied at all times in Zones III and IV.

Magnetic Field Hazards

Static Magnetic Field (B0)

The most dangerous MRI hazard is the projectile (missile) effect. Ferromagnetic objects brought near the magnet bore experience a powerful translational force proportional to the spatial gradient of the magnetic field (strongest near the bore opening), which can accelerate them toward the scanner with potentially lethal force. Objects that seem non-magnetic at low field strengths may become dangerous projectiles at 1.5T or 3T. Documented projectile incidents have involved oxygen cylinders, IV poles, wheelchairs, floor buffers, and firearms. Prevention relies on rigorous screening, ferromagnetic detection systems at the Zone III/IV boundary, and ensuring that only non-ferromagnetic equipment enters Zone IV.

Ferromagnetic objects inside the magnet also experience torque, a rotational force that tends to align them with the B0 field lines. This is particularly relevant for implanted ferromagnetic objects such as certain aneurysm clips, cardiac valves, and metallic foreign bodies. Torque is maximal within the uniform center of the magnet.

The static magnetic field at clinical strengths (up to 3T) is generally considered safe for biological tissues. Mild transient effects such as vertigo, nausea, and metallic taste have been reported, especially at ultra-high field strengths like 7T. The magnetohydrodynamic effect, in which blood flowing through the strong magnetic field induces a voltage, causes an augmented T-wave on the ECG. This is an artifact and does not represent a cardiac effect.

Gradient Magnetic Fields

Rapidly switching gradient fields can induce electrical currents in tissue, causing peripheral nerve stimulation (PNS) that manifests as tingling, twitching, or muscle contraction, typically in the extremities. The FDA limits the rate of gradient switching (dB/dt) to levels well below the threshold for cardiac stimulation. PNS is more common at 3T and with high-performance gradient systems.

Gradient coil vibration produces substantial acoustic noise, reaching up to 130 dB in some sequences. Hearing protection is mandatory for all patients, and this is a particular concern in pediatric and sedated patients who cannot report discomfort.

Radiofrequency (RF) Field

RF energy deposited in tissue is measured as the Specific Absorption Rate (SAR), expressed in watts per kilogram. SAR is proportional to B0 squared, meaning it quadruples when moving from 1.5T to 3T. The FDA sets limits at 4 W/kg for whole-body SAR over 15 minutes and 3.2 W/kg for head SAR. Factors that increase SAR include higher field strength, higher flip angles, more RF pulses per sequence, and larger patient body habitus. Conductive implants can act as antennas, concentrating RF energy and creating a risk of localized tissue heating.

RF burns can also occur even without implants. Skin-to-skin contact, monitoring leads, or looped cables can concentrate RF-induced currents and cause burns. Prevention involves ensuring no skin-to-skin contact, avoiding loops in cables, using MR-conditional monitoring equipment, and placing padding between the patient and the bore.

Implant and Device Safety

Classification System

The ASTM International classification system defines three categories. MR Safe devices pose no known hazards in any MR environment and are typically non-metallic, non-conductive items. MR Conditional devices are safe only under specific conditions, such as defined field strength, SAR limits, gradient slew rate, and device positioning. Most modern implants fall into this category, and the specific conditions must be verified and met for every scan. MR Unsafe devices pose unacceptable risk in all MR environments, such as certain ferromagnetic aneurysm clips and some older cardiac devices.

Cardiac Implantable Electronic Devices (CIEDs)

An increasing number of pacemakers and implantable cardioverter-defibrillators (ICDs) are now designated MR Conditional. Scanning these patients requires device interrogation and programming to MR mode (for example, asynchronous pacing) before the scan, followed by post-scan interrogation and reprogramming. Institutional protocols must include cardiology or electrophysiology involvement. Specific conditions, usually including field strength limited to 1.5T and defined SAR and scan duration limits, must be strictly followed. Non-MR Conditional (legacy) devices are generally considered MR Unsafe, although scanning may be considered at specialized centers on a case-by-case basis when benefit strongly outweighs risk, following ACC/AHA/HRS guidelines. Risks include lead heating, device malfunction, inappropriate pacing or shocks, and lead tip migration.

Specific Implants of Concern

Ferromagnetic intracranial aneurysm clips are an absolute contraindication to MRI. Most clips placed since the mid-1990s are MR Conditional, being made of titanium or non-ferromagnetic alloys, but verification is mandatory. Most modern cochlear implants are MR Conditional at 1.5T with specific precautions, and some models require magnet removal before scanning. Orbital metallic foreign bodies require screening with history and, when indicated, orbit radiographs before MRI. Most modern joint replacements and spinal hardware made of titanium are MR Conditional, with the primary concern being image artifact rather than safety. Most vascular stents are MR Conditional after a waiting period of typically 6 to 8 weeks to allow endothelialization.

Screening Process

Every patient must complete a comprehensive written screening questionnaire before every MRI examination, even if they have been scanned previously, since they may have acquired new implants. A Level 2 MRI Personnel member must verbally review all positive responses. When the status of an implant is uncertain, the manufacturer documentation, surgical records, or an MRI safety reference database (such as MRISafety.com) should be consulted. If any doubt remains about the safety of a potentially ferromagnetic implant, the scan should not proceed.

Gadolinium-Based Contrast Agents (GBCAs)

Types of GBCAs

GBCAs are divided into two structural categories. Linear agents (gadopentetate dimeglumine/Magnevist, gadodiamide/Omniscan, gadoversetamide/OptiMARK) have an open-chain molecular structure that is more prone to releasing free gadolinium through a process called transmetallation. They are associated with a higher risk of nephrogenic systemic fibrosis and greater gadolinium deposition in the brain. Macrocyclic agents (gadoterate meglumine/Dotarem, gadobutrol/Gadavist, gadoteridol/ProHance) have a cage-like molecular structure that holds gadolinium more tightly, providing greater thermodynamic stability. Macrocyclic agents are preferred in current practice. For NSF risk stratification, Group II agents (gadodiamide, gadopentetate dimeglumine, gadoversetamide) carry the highest risk, while Group III agents (macrocyclic agents and gadobenate dimeglumine/MultiHance) carry the lowest.

Nephrogenic Systemic Fibrosis (NSF)

NSF is a systemic fibrosing disorder affecting the skin, joints, and internal organs. It occurs almost exclusively in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m^2) or those on dialysis, and is strongly associated with Group II linear GBCAs. No confirmed unconfounded cases have been reported with Group III agents used at standard doses. The ACR recommends screening eGFR before GBCA administration in patients with known or suspected renal disease, those older than 60, and those with hypertension, diabetes, or hepatorenal syndrome. If eGFR is below 30, Group II agents should be avoided entirely. Group III agents may be used if clinically essential, with informed consent.

Gadolinium Deposition in the Brain

Increased T1 signal in the dentate nucleus and globus pallidus has been observed after multiple GBCA administrations, and is more pronounced with linear agents than macrocyclic agents. The clinical significance of this deposition remains uncertain, and no neurological symptoms have been definitively attributed to it. The FDA has not restricted GBCA use but recommends limiting exposure to situations where clinical benefit outweighs potential risk. The current practice trend is to preferentially use macrocyclic agents.

Acute Adverse Reactions

The overall incidence of adverse reactions to GBCAs is low (0.07 to 0.77%), much lower than with iodinated contrast agents. Most reactions are mild, including nausea, headache, injection site discomfort, and dizziness. Severe anaphylactoid reactions are rare (approximately 0.001 to 0.01%) and are managed with standard anaphylaxis protocols. Premedication with corticosteroids should be considered for patients with a prior GBCA reaction.

Special Patient Populations

Pregnancy

No harmful effects of MRI on the fetus have been proven at clinical field strengths, though theoretical concerns about thermal effects remain. ACR guidance states that MRI may be used at any gestational age when the clinical information cannot be obtained by a non-ionizing alternative and is needed during the pregnancy. Gadolinium crosses the placenta and is excreted into amniotic fluid, creating a theoretical concern about free gadolinium exposure to the fetus. GBCAs should therefore be avoided during pregnancy unless absolutely essential for maternal diagnosis. Studies have shown a small association between first-trimester gadolinium exposure and rheumatological or inflammatory conditions in offspring.

Pediatric Patients

The same safety considerations regarding implants and ferromagnetic screening that apply to adults also apply to children. Acoustic noise protection is critical and ear protection is mandatory. Sedation and anesthesia risks must be evaluated independently of MRI safety considerations. Feed-and-sleep protocols for neonates and infants can often avoid the need for sedation. All equipment used in Zone IV must be MR Conditional and appropriately sized for pediatric patients.

<image>A floor plan diagram of an MRI suite showing the four ACR safety zones. Zone I (green) is the general public waiting area with unrestricted access. Zone II (yellow) is the screening and reception area where patients complete safety questionnaires. Zone III (orange) is the controlled access area requiring Level 1 or Level 2 personnel clearance, containing the MRI control room and patient preparation area, with a physical barrier (locked door or gate) separating it from Zone II. Zone IV (red) is the scanner room containing the magnet, patient table, and coils, accessed through a second controlled doorway from Zone III. A ferromagnetic detection system is positioned at the Zone III to Zone IV transition. The 5-Gauss fringe field line is shown as a dashed boundary within Zone IV and partially extending into adjacent areas.</image>

<image>A visual reference showing the three MRI implant safety classification labels as defined by ASTM International. The MR Safe label is a green square with a white "MR" text. The MR Conditional label is a yellow triangle with "MR" text and specific conditions listed below (field strength, SAR limit, gradient slew rate). The MR Unsafe label is a red circle with a diagonal line through "MR" text. Below each label, example devices are listed: MR Safe (plastic wheelchair, copper IUD), MR Conditional (titanium hip prosthesis, MR conditional pacemaker), and MR Unsafe (certain ferromagnetic cerebral aneurysm clips, some older cochlear implants). A warning box emphasizes that MR Conditional devices require verification of specific conditions before every scan.</image>

Clinical Pearls

The projectile hazard is the leading cause of MRI-related injuries and deaths. No object should enter Zone IV unless it has been confirmed as MR Safe or MR Conditional for the specific scanner in use. Every patient must be screened with both a written questionnaire and a verbal interview before every MRI, because patients may have acquired new implants since their last scan. When scanning patients with MR Conditional CIEDs, institutional protocol must be followed strictly, including pre- and post-scan device interrogation; non-MR Conditional devices should never be scanned without a comprehensive risk-benefit analysis at an experienced center. Macrocyclic GBCAs should be used preferentially over linear agents to minimize both NSF risk and gadolinium deposition in the brain. Renal function (eGFR) should be screened in at-risk patients before GBCA administration, and Group II agents should be entirely avoided if eGFR is below 30 mL/min. RF burns can occur from skin-to-skin contact or conductive loops even in the absence of any implants, making proper patient positioning and padding essential safety steps.

References

• ACR Manual on MR Safety, 2024 edition (American College of Radiology Committee on MR Safety)
• Shellock FG, Spinazzi A. "MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis." AJR, 2008
• Kanal E, et al. "ACR Guidance Document on MR Safe Practices: Updates and Critical Information." JMRI, 2013
• FDA Drug Safety Communication: "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body," 2017
• Indik JH, et al. "2017 HRS Expert Consensus Statement on Magnetic Resonance Imaging and Radiation Exposure in Patients With Cardiovascular Implantable Electronic Devices." Heart Rhythm, 2017

Read this lecture as Markdown